Epstein-Barr virus infection in sarcomatoid renal cell carcinoma tissues

BJU International

Volumn 96, Issue 4, 2005, Pages 547-552

  Kim, Kwang Hee ^b   Han, Eun Mee ^a   Lee, Eung Seok ^a   Park, Hong Seok ^a   Kim, Insun ^a   Kim, Young Sik ^a  

^a Korea University College of Medicine   (South Korea)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Epstein Barr virus infections; Renal cell carcinoma; Tumour infiltrating lymphocytes

Indexed keywords

CELL MARKER; COMPLEMENT COMPONENT C3D RECEPTOR; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ENCODED NUCLEAR ANTIGEN 1; EPSTEIN BARR VIRUS ENCODED NUCLEAR ANTIGEN 3C; ESPTEIN BARR VIRUS ENCODED NUCLEAR ANTIGEN 2; GENE PRODUCT; IMMEDIATE EARLY PROTEIN BZLF1; LATENT MEMBRANE PROTEIN 1; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMEDIATE EARLY GENE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; LYMPHOID CELL; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; PLASMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SARCOMA; SIGNAL DETECTION; SURVIVAL RATE; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; VIRUS INFECTION; VIRUS REPLICATION;

ADULT; AGED; ANTIGENS, VIRAL; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CARCINOMA, RENAL CELL; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; GENOTYPE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KIDNEY NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; MIXED TUMOR, MALIGNANT; POLYMERASE CHAIN REACTION; RECEPTORS, COMPLEMENT 3D; RNA, VIRAL; SARCOMA; VIRUS LATENCY;

EID: 24044469011     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05682.x     Document Type: Article

References (22)

1. Storkel S, Eble JN, Adlakha K et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997; 80: 987-9
2. Delahunt B. Sarcomatoid renal carcinoma: the final common dedifferentiation pathway of renal epithelial malignancies. Pathology 1999; 31: 185-90
3. Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 1999; 17: 523-8
4. Murray PG, Young LS. Epstein-Barr virus infection: basis of malignancy and potential for therapy. Expert Rev Mol Med 2001; 15: 1-20
5. Israel BF, Kenney SC. Virally targeted therapies for EBV-associated malignancies. Oncogene 2003; 22: 5122-30
6. Gazzaniga P, Vercillo R, Gradilone A et al. Prevalence of papillomavirus, Epstein-Barr virus, cytomegalovirus, and herpes simplex virus type 2 in urinary bladder cancer. J Med Virol 1998; 55: 262-7
7. Chuang CK, Liao SK. Epstein-Barr virus infection in urothelial transitional cell carcinoma tissues. BJU Int 2004; 93: 495-8
8. Becker JL, Miller F, Nuovo GJ, Josepovitz C, Schubach WH, Nord EP. Epstein-Barr virus infection of renal proximal tubule cells: possible role in chronic interstitial nephritis. J Clin Invest 1999; 104: 1673-81
9. Joh K, Kanetsuna Y, Ishikawa Y et al. Epstein-Barr virus genome-positive tubulointerstitial nephritis associated with immune complex-mediated glomerulonephritis in chronic active EB virus infection. Virchows Arch 1998; 432: 567-73
10. Iwama H, Horikoshi S, Shirato I, Tomino Y. Epstein-Barr virus detection in kidney biopsy specimens correlates with glomerular mesangial injury. Am J Kidney Dis 1998; 32: 785-93
11. International Union Against Cancer. TNM Classification of Malignant Tumors, 6th edn. New York, NY: Wiley-Liss, 2002: 193-5
12. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-63
13. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997; 10: 537-44
14. Sixbey JW, Yao QY. Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism. Science 1992; 255: 1578-80
15. Imai S, Nishikawa J, Takada K. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol 1998; 72: 4371-8
16. Sample J, Young L, Martin B et al. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol 1990; 64: 4084-92
17. de Peralta-Venturina M, Moch H, Amin M et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 2001; 25: 275-84
18. Laichalk LL, Hochberg D, Babcock GJ, Freeman RB, Thorley-Lawson DA. The dispersal of mucosal memory B cells: evidence from persistent EBV infection. Immunity 2002; 16: 745-54
19. Uzzo RG, Cairns P, Al-Saleem T et al. The basic biologyand immunobiology of renal cell carcinoma: considerations for the clinician. Urol Clin North Am 2003; 30: 423-36
20. Zeisberg M, Kalluri R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med 2004; 82: 175-81
21. di Renzo L, Altiok A, Klein G, Klein E. Endogenous TGF-beta contributes to the induction of the EBV lytic cycle in two Burkitt lymphoma cell lines. Int J Cancer 1994; 57: 914-9
22. Cheville JC, Lohse CM, Zincke H et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 2004; 28: 435-41